Thousands of women in England could be spared painful cancer examinations thanks to a new AI-powered blood test being trialled at several NHS hospitals. The PinPoint blood test aims to reduce the need for invasive procedures among postmenopausal women referred for suspected womb cancer.
AI Blood Test Revolutionizes Cancer Screening
Every year, approximately 90,000 postmenopausal women in England are referred by their GPs due to heavy bleeding, which raises concerns about womb cancer, also known as endometrial cancer. Out of these, around 10,000 women are diagnosed, and 2,700 succumb to the disease. The new blood test, currently under trial at two NHS trusts, could potentially spare 18,000 women annually from undergoing unnecessary transvaginal ultrasound scans.
During the trial involving 16,481 patients, the blood test demonstrated a remarkable 99% accuracy rate in detecting gynaecological cancers among women referred due to bleeding concerns. This accuracy surpasses that of conventional testing methods, which often involve multiple invasive procedures.
How the PinPoint Test Works
The PinPoint blood test was developed by PinPoint Data Science, a Leeds-based firm specializing in medical data analysis. Utilizing machine learning, the test evaluates 30 blood markers to determine a patient's risk level for cancer, categorizing them as low, elevated, or high risk.
According to Prof Sean Duffy, the firm’s chief medical officer, the test’s ability to safely rule out low-risk women “is remarkable by any clinical standards.” This innovation could significantly reduce the number of unnecessary invasive procedures and help healthcare professionals focus on patients who truly require treatment.
Impact on NHS Resources and Patient Experience
Dr Jacinta Walsh, a GP at King’s Medical Practice in Normanton, West Yorkshire, noted that it often takes up to six visits to a GP to rule out cancer. The PinPoint test could streamline this process, providing peace of mind for patients and freeing up resources for other medical needs.
Brent Kilmurray, chief executive of the Mid Yorkshire NHS Trust, emphasized the compelling case for implementing the test in hospitals. He stated that if doctors can confidently rule out low-risk women in primary care, it could lead to reduced waiting lists and earlier diagnoses for those with cancer.
- 90,000 women referred annually for heavy bleeding
- 10,000 diagnosed with womb cancer each year
- 2,700 deaths from womb cancer annually
- 18,000 women potentially spared from ultrasound scans
- 99% accuracy rate in detecting gynaecological cancers
Cancer Research UK has expressed cautious optimism about the PinPoint test, with spokesperson Samantha Harrison stating, “Spotting cancer early saves lives, but right now patients are not being diagnosed quickly enough.” More research is necessary to understand the full benefits for patients and the NHS, but initial results are promising.
🤖 This article was rewritten by Feed and Figures' editorial AI from a report originally published by Guardian Health. Facts and quotes are preserved from the original; the rewrite focuses on clarity and structure. For the unedited original, see the source link below.
